17/12/19 -"We have hiked our estimates on account of: 1. Faster than expected growth in the acquired Osiris business, which will result in a material uplift in the performance of the wound care business 2. ..."
Pages
67
Language
English
Published on
17/12/19
You may also be interested by these reports :
23/10/26
SSB delivered an in-line Q3 26, with revenue and underlying EBITDA in line with consensus. Consumables continued to lead growth, while equipment grew ...
22/10/26
After a failed bid by Thermo Fisher and persistent rumours in recent years, Qiagen shareholders now have a second opportunity. Although shareholder ...
22/10/26
Sartorius reported a strong Q3 26, with revenue (+3.0%) and underlying EBITDA (+4.1%) comfortably ahead of consensus. Operational growth accelerated ...
20/10/26
EssilorLuxottica recorded strong growth in Q3 2026, ahead of market expectations, with revenue up 9.0% YoY and 7.2% at constant currency. Management ...